OncoSil Medical Limited (ASX:OSL)
0.6450
0.00 (0.00%)
Nov 17, 2026, 10:35 AM AEDT
OncoSil Medical Earnings Call Transcripts
Fiscal Year 2026
-
FDA granted HDE approval for OncoSil, the first Class III device for unresectable, non-metastatic distal cholangiocarcinoma, enabling U.S. marketing with initial use limited to five centers and 30 patients. Broader rollout and revenue depend on completing a post-approval study, with full launch targeted for the second half of FY 2027.